fenfluramine has been researched along with Liver Steatosis in 2 studies
Fenfluramine: A centrally active drug that apparently both blocks serotonin uptake and provokes transport-mediated serotonin release.
fenfluramine : A secondary amino compound that is 1-phenyl-propan-2-amine in which one of the meta-hydrogens is substituted by trifluoromethyl, and one of the hydrogens attached to the nitrogen is substituted by an ethyl group. It binds to the serotonin reuptake pump, causing inhbition of serotonin uptake and release of serotonin. The resulting increased levels of serotonin lead to greater serotonin receptor activation which in turn lead to enhancement of serotoninergic transmission in the centres of feeding behavior located in the hypothalamus. This suppresses the appetite for carbohydrates. Fenfluramine was used as the hydrochloride for treatment of diabetes and obesity. It was withdrawn worldwide after reports of heart valve disease and pulmonary hypertension.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To validate a variation of a well-established magnetic resonance imaging (MRI) technique to detect liver fat and use it to monitor liver fat changes after treatment with dexfenfluramine in men with non-insulin dependent diabetes mellitus (NIDDM)." | 3.69 | Measurement of liver fat by MRI and its reduction by dexfenfluramine in NIDDM. ( Clark, ML; Hockaday, TD; Marks, SJ; Moore, NR; Pointon, JJ; Ryley, NG; Strauss, BJ, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Marks, SJ | 1 |
| Moore, NR | 1 |
| Ryley, NG | 1 |
| Clark, ML | 1 |
| Pointon, JJ | 1 |
| Strauss, BJ | 1 |
| Hockaday, TD | 1 |
| DeMeo, MT | 1 |
| Mobarhan, S | 1 |
| Mikolaitis, S | 1 |
| Kazi, N | 1 |
2 other studies available for fenfluramine and Liver Steatosis
| Article | Year |
|---|---|
Measurement of liver fat by MRI and its reduction by dexfenfluramine in NIDDM.
Topics: Adult; Biopsy; Confidence Intervals; Diabetes Mellitus; Diabetes Mellitus, Type 2; Fatty Liver; Fema | 1997 |
Three cases of comprehensive dietary therapy and pharmacotherapy of patients with complex obesity-related diseases.
Topics: Adult; Aged; Appetite Depressants; Diabetes Mellitus, Type 2; Diet, Reducing; Fatty Liver; Female; F | 1997 |